STOCK TITAN

NexImmune to Present at the 2021 Barclays Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

GAITHERSBURG, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will present a company overview at the virtual 2021 Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 10:55 a.m. Eastern time.

The presentation will be accessible via live webcast by visiting https://ir.neximmune.com/investors/events-and-presentations. A replay will be available on the NexImmune website following the presentation.

About NexImmune

NexImmune, based in Gaithersburg, Maryland, is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells to generate a specific, potent and durable immune response that mimics natural biology. For more information, visit www.neximmune.com.

Contacts

Investors:
Chad Rubin
Solebury Trout
646-378-2947
crubin@soleburytrout.com 

Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312-961-2502
mikebeyer@sambrown.com 


Neximmune Inc

NASDAQ:NEXI

NEXI Rankings

NEXI Latest News

NEXI Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About NEXI

neximmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary aim™ technology. this nanotechnology platform, originally developed at johns hopkins university, is the foundation for an innovative approach to immunotherapy in which the body’s own immune system is stimulated to orchestrate a targeted t cell response against a disease. central to the aim technology are artificial antigen presenting cells (aapc) that present antigens to t cells eliciting a highly targeted therapy driven by the patient’s immune system. these aapc can be rapidly engineered to elicit a specific immune attack that can be directed toward any foreign substance or cell type in a patient’s body.